| Metric | Current Period | Prior-Year Period | YoY |
|---|---|---|---|
| Revenue / Net Sales | ¥1083.7B | ¥918.1B | +18.0% |
| Operating Income | ¥374.1B | ¥257.1B | +45.5% |
| Ordinary Income | ¥372.1B | ¥255.9B | +45.4% |
| Net Income | ¥267.2B | ¥88.2B | +203.2% |
| ROE | 16.0% | 5.8% | - |
The cumulative Q3 results for FY2026 (9 months) show Revenue ¥1,083.7B (YoY +¥165.5B +18.0%), Operating Income ¥374.1B (YoY +¥117.0B +45.5%), Ordinary Income ¥372.1B (YoY +¥116.1B +45.4%), and Quarterly Net Income attributable to owners of parent ¥266.6B (YoY +¥178.9B +203.2%), delivering significant revenue and profit growth across all stages. The operating profit growth rate (+45.5%), which far outpaced revenue growth, was driven by simultaneous improvement in gross margin to 70.9% (YoY +3.1pt) and SG&A ratio to 36.3% (YoY -3.5pt), expanding the operating margin to 34.5% (prior year 28.0%) for a +6.5pt increase. The large jump in Net Income (+203.2%) was aided by a shift to net-positive non-recurring items due to a gain on sale of investment securities of ¥15.3B recorded as a special gain in addition to the strong operating performance. Progress vs. full-year plan stood at Revenue 76.7%, Operating Income 88.6%, and Net Income 87.3%, well above the Q3 benchmark of 75%, indicating upside potential.
[Revenue] Revenue ¥1,083.7B (YoY +18.0%) was driven by double-digit growth in both the core Medical Business at ¥947.7B (YoY +14.6%) and the Devices Business at ¥262.5B (YoY +32.1%). Sales composition was Medical 87.5%, Devices 24.2% (before intersegment eliminations), with Medical providing scale and Devices providing higher growth. External-customer sales were 78.3% from Medical, and the high-value product mix and market expansion in Medical were the primary contributors to companywide top-line growth. The Devices Business grew strongly at +32.1% YoY, aided by new customer wins and volume increases.
[Profitability] Cost of sales increased to ¥315.8B (YoY +6.9%) as a natural increase with sales, but this was well below the sales growth rate of +18.0%, resulting in Gross Profit ¥767.9B (YoY +23.3%) and Gross Margin improved to 70.9% (prior year 67.8%, +3.1pt). SG&A was controlled at ¥393.7B (YoY +7.7%), compressing the SG&A ratio to 36.3% (prior year 39.8%, -3.5pt). Consequently, Operating Income rose to ¥374.1B (YoY +45.5%) and Operating Margin improved to 34.5% (prior year 28.0%, +6.5pt). Ordinary Income ¥372.1B reflected continued operating strength; non-operating items included foreign exchange losses ¥3.7B and interest expenses ¥1.0B, both with limited impact. Non-recurring items resulted in a net positive ¥5.8B: a gain on sale of investment securities ¥15.3B offset impairment losses ¥93.0B and valuation losses on investment securities ¥1.6B. In the prior year, non-recurring items were a net negative ¥106.1B, so Net Income increased substantially to ¥266.6B (YoY +203.2%). In conclusion, double-digit revenue growth, large operating-level profitability improvements, and a turn to net-positive non-recurring items combined to produce a strong earnings beat.
The Medical Business achieved Revenue ¥947.7B (YoY +14.6%), Operating Income ¥361.3B (YoY +31.8%), and Operating Margin 38.1% (prior year 33.2%, +4.9pt), delivering high profitability alongside growth. This segment accounted for 96.6% of consolidated Operating Income and remains the earnings core. Expansion of high-value product sales and better absorption of fixed costs drove the 4.9pt margin improvement. The Devices Business posted Revenue ¥262.5B (YoY +32.1%), Operating Income ¥72.7B (YoY +88.6%), and Operating Margin 27.7% (prior year 19.4%, +8.3pt), realizing profit growth that outpaced revenue growth. Scale-driven fixed-cost absorption and production-efficiency improvements contributed to the large margin uplift. Before intersegment eliminations, the two segments generated combined Operating Income ¥434.1B (pre-adjustment) against consolidated Operating Income ¥374.1B, indicating high profitability maintained after corporate-level expense adjustments.
[Profitability] Operating Margin 34.5% improved +6.5pt from 28.0% a year earlier, and Net Margin 24.7% expanded +15.1pt from 9.6% a year earlier. Simultaneous improvements in Gross Margin 70.9% (YoY +3.1pt) and SG&A ratio 36.3% (YoY -3.5pt) drove operating profitability. [Return on Investment] ROE 16.0% markedly improved from 5.8% in the prior-year period. DuPont decomposition shows Net Margin 24.7% (prior year 9.6%), Total Asset Turnover 0.53x (prior year 0.48x), and Financial Leverage 1.22x (prior year 1.28x), with Net Margin improvement being the main driver. The improvement in Total Asset Turnover reflects Sales growth +18.0% versus a modest increase in Total Assets (YoY +5.5%). [Financial Soundness] Equity Ratio 82.0% (prior year 77.9%, +4.1pt) is extremely high, with Net Assets ¥1,671.6B against Total Assets ¥2,037.3B. Interest-bearing debt was reduced to Short-term Borrowings ¥23.7B and Long-term Borrowings ¥48.6B, total ¥72.3B (prior year ¥90.2B, -19.8%), indicating deleveraging progress. Current Ratio 503.9% (prior year 371.1%) and Quick Ratio 461.7% (prior year 338.6%) show solid short-term liquidity. Cash and deposits ¥598.0B are 2.6x current liabilities ¥227.3B, minimizing short-term funding risk. [Cash Quality] From a working-capital perspective, Accounts Receivable ¥191.8B (prior year ¥157.7B, +21.7%), Inventories ¥95.8B (prior year ¥94.1B, +1.8%), and Accounts Payable ¥33.8B (prior year ¥26.6B, +27.3%) indicate increases in receivables and payables in line with sales growth. Inventory growth lags sales growth, suggesting generally good inventory management.
A cash flow statement was not disclosed, so funding trends are analyzed from balance-sheet movements. Cash and deposits increased to ¥598.0B (prior year ¥542.0B, +¥56.0B), maintaining abundant liquidity. Interest-bearing debt was reduced to ¥72.3B (prior year ¥90.2B, -¥17.9B), expanding the net cash position to ¥525.7B (prior year ¥451.8B, +¥73.9B). Estimated working capital change—Accounts Receivable increase +¥34.2B, Inventories increase +¥1.7B, Accounts Payable increase +¥7.2B—implies working capital expanded by approximately +¥28.7B, within the natural increase from sales growth. Investment securities declined to ¥185.3B (prior year ¥193.9B, -¥8.6B), consistent with the ¥15.3B gain on sale of securities recorded as a special gain. Tangible fixed assets rose to ¥602.4B (prior year ¥590.8B, +¥11.6B), suggesting continued investment to expand production capacity. Treasury stock fell sharply to ¥0.2B (prior year ¥44.5B, -¥44.3B), indicating cancellation or disposal of treasury shares. Retained earnings increased to ¥1,060.2B (prior year ¥979.5B, +¥80.7B), reflecting accumulation of Net Income ¥266.6B. Overall, funds generated from operating activities have been directed toward cash accumulation and reduction of interest-bearing debt, further strengthening the financial structure.
Operating Income ¥374.1B (Operating Margin 34.5%) reflects recurring earnings from a highly profitable core business. Non-operating items were net -¥2.1B (Non-operating income ¥5.3B, Non-operating expenses ¥7.3B), a minor -0.2% of Revenue, primarily due to foreign exchange losses ¥3.7B and interest expense ¥1.0B. Non-recurring items were net +¥5.8B (Special gains ¥15.3B, Special losses ¥9.5B), with the gain on sale of investment securities ¥15.3B recorded as a one-time benefit. Special losses included impairment losses ¥93.0B (same amount recorded in the prior year) and valuation losses on investment securities ¥1.6B. The difference between Ordinary Income ¥372.1B and Income before income taxes ¥377.9B is +¥5.8B, reflecting the net-positive effect of non-recurring items boosting Net Income. Because the prior-year non-recurring items were net -¥106.1B, improvement in special items was a major contributor to the substantial YoY Net Income increase (+203.2%). Of Net Income ¥266.6B, the contribution from operating income—approximated as ¥374.1B × (1 - tax burden)—is about ¥268B, indicating the majority of Net Income was generated from core operations. However, the ¥15.3B gain on sale of investment securities is transient and should be normalized in projections for subsequent periods. Comprehensive Income ¥328.7B exceeded Net Income ¥267.2B by ¥61.5B, driven by Other Comprehensive Income +¥61.4B (Foreign Currency Translation Adjustments +¥65.5B, Valuation Differences on Available-for-sale Securities -¥3.5B, Remeasurements of Defined Benefit Plans -¥0.5B). The positive foreign currency translation adjustment reflects valuation gains on overseas assets from yen depreciation; since this includes temporary elements, divergence from Net Income warrants attention.
The full-year forecasts remain unchanged at Revenue ¥1,411.4B (YoY +17.6%), Operating Income ¥422.2B (YoY +40.4%), Ordinary Income ¥426.9B (YoY +44.4%), and Net Income attributable to owners of parent ¥305.6B. Progress vs. the cumulative Q3 results is Revenue 76.7% (Q3 benchmark 75% +1.7pt), Operating Income 88.6% (benchmark +13.6pt), Ordinary Income 87.2% (benchmark +12.2pt), and Net Income 87.3% (benchmark +12.3pt), confirming significant front-loading of profits. The Operating Income progress of 88.6% implies ¥48.1B of Operating Income remains to be generated in Q4, which — based on Q3 standalone Operating Income performance — appears achievable. The Net Income progress of 87.3% is also within an achievable range, suggesting upside potential. The company has not revised guidance this quarter and may be maintaining conservative forecasts. If special items or seasonal effects occur in Q4, some of the progress could be absorbed, but current progress is very healthy.
No dividends were paid in the current quarter to date; the full-year dividend forecast is ¥46.10 per share (prior year ¥43.70, +5.5%). Based on 265,332 thousand shares outstanding (after deducting 8 thousand treasury shares), the annual dividend payout is approximately ¥122B, implying a Payout Ratio of about 40% against the full-year Net Income forecast ¥305.6B, a sustainable level. The prior-year payout ratio was approximately 38% on a ¥43.70 dividend / EPS ¥114.88 basis; the company appears to maintain a higher dividend while slightly increasing the payout ratio. Cash and deposits ¥598.0B and interest-bearing debt ¥72.3B produce a net cash position of ¥525.7B, equivalent to 4.3 years of the dividend outflow, supporting dividend sustainability. No disclosure on share repurchases was made; shareholder returns are currently concentrated on dividends. Total Return Ratio equals the dividend payout ratio, approximately 40%.
Working capital management risk: The increase in Accounts Receivable to ¥191.8B (YoY +21.7%) exceeds the sales growth rate of +18.0%, suggesting potential elongation of collection periods. Broadly defined inventories — including Inventories ¥95.8B, Work-in-progress ¥96.9B, and Raw Materials ¥74.7B — total ¥267.4B, representing 24.7% of Revenue and indicating a certain level of inventory carry. Continued working-capital expansion could pressure operating cash flow generation and slow growth in cash on hand.
Reversal risk of one-off items: Of Net Income ¥266.6B, the gain on sale of investment securities ¥15.3B (5.7% of Net Income) is a one-time benefit and should be normalized in future expectations. The prior-year large special loss (net -¥106.1B) depressed Net Income to ¥88.2B, so the YoY +203.2% increase largely reflects the swing in non-recurring items. Future Net Income should be assessed primarily on operating profitability (Operating Margin 34.5%), and fluctuations in special items could materially affect Net Income.
Segment concentration risk: The Medical Business accounts for 78.3% of Revenue and 96.6% of Operating Income, indicating high single-segment dependence. Regulatory changes specific to the medical device industry (e.g., marketing approvals, insurance reimbursement price revisions), intensifying competition, or shifts in bargaining power could materially impact companywide performance. The Devices Business, despite high growth (+32.1%), remains small in scale (Revenue ¥262.5B), limiting diversification benefits.
Profitability & Return
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Margin | 34.5% | 8.9% (5.4%–12.7%) | +25.7pt |
| Net Margin | 24.7% | 6.5% (3.3%–9.4%) | +18.2pt |
The company’s Operating Margin 34.5% and Net Margin 24.7% substantially exceed manufacturing-sector medians, indicating top-tier profitability.
Growth & Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth Rate (YoY) | 18.0% | 2.8% (-1.5%–8.8%) | +15.2pt |
The company’s Revenue growth rate 18.0% far exceeds the manufacturing median 2.8%, confirming its position as a high-growth company.
※ Source: Company compilation
High profitability in the Medical Business combined with high-growth Devices Business produced an Operating Margin of 34.5% (industry median +25.7pt), demonstrating extremely strong profitability. Simultaneous improvements in Gross Margin 70.9% and SG&A ratio 36.3% expanded Operating Margin by +6.5pt YoY, reflecting a continued trend of margin improvement. Progress vs. full-year guidance is strong—Operating Income 88.6% and Net Income 87.3% at Q3—suggesting upside potential.
The financial position is robust with Equity Ratio 82.0% and net cash ¥525.7B, and deleveraging (YoY -19.8% in interest-bearing debt) is progressing. The Payout Ratio around 40% is sustainable, and ample cash balance ¥598.0B supports dividend sustainability. However, the large YoY increase in Net Income (+203.2%) was aided by a ¥15.3B gain on sale of investment securities and a reversal from the prior-year large special loss; future profit levels should be based on operating profitability (Operating Margin 34.5%). The increase in working capital (Accounts Receivable +21.7%, broad inventory ¥267.4B) necessitates monitoring of the sustainability of operating cash-flow generation.
This report was automatically generated by AI analyzing XBRL financial statement data. It is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled by the company based on public financial statements. Investment decisions are your own responsibility; consult a professional if necessary.